Skip to content
Doctor licensed in Poland · PWZ 3211301 Prescription on the EU model Every day, 5am to 11pm (Irish time)

Mounjaro, Wegovy and Ozempic compared

Three product names dominate questions about weight management medicines in Ireland, and two of them contain the same active substance. Wegovy and Ozempic are both semaglutide; Mounjaro is tirzepatide, which acts on a second receptor as well. This page compares them on the points that matter to you: the licensed use, the dose schedule, the side effects and what the trials did and did not show. It is information about prescription medicines, not a recommendation of any of them.

The short version

Wegovy and Ozempic contain semaglutide, a GLP-1 receptor agonist injected once a week. Mounjaro contains tirzepatide, which acts on the GIP and GLP-1 receptors and is also injected once a week. A fourth product often mentioned alongside them, Saxenda, contains liraglutide and is injected once a day.

The licensed uses differ. Wegovy, Mounjaro and Saxenda are licensed for weight management. Ozempic is licensed only for type 2 diabetes, so using it for weight loss alone falls outside its licence. In the HPRA list of authorised medicines, every licence of these four products is prescription only and may not be renewed (category A).

ProductActive substanceLicensed use (SmPC 4.1)How oftenDose schedule (SmPC 4.2)
MounjaroTirzepatideWeight management in adults; type 2 diabetes from age 10Once a week2.5 mg for 4 weeks, then 5 mg; 2.5 mg steps after at least 4 weeks; maintenance 5, 10 or 15 mg, maximum 15 mg
WegovySemaglutideWeight management in adults; the injection also from age 12Injection once a week; tablet once a dayInjection: 0.25 mg rising every 4 weeks to 2.4 mg after 16 weeks, 7.2 mg possible in some adults. Tablet: 1.5 mg rising to 25 mg
OzempicSemaglutideType 2 diabetes in adults onlyOnce a week0.25 mg for 4 weeks, then 0.5 mg; possible steps to 1 mg and 2 mg after at least 4 weeks each; maximum 2 mg
SaxendaLiraglutideWeight management in adults; also from age 6 with weight criteriaOnce a day0.6 mg rising by 0.6 mg at least weekly to 3.0 mg

What is in each pen

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1, according to the Wegovy summary of product characteristics (SmPC). It binds to and activates the GLP-1 receptor, which is present in areas of the brain involved in appetite regulation. The SmPC reports that it reduces energy intake, increases feelings of fullness and reduces hunger and cravings.

Tirzepatide is a long-acting agonist at both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor. The Mounjaro SmPC describes a similar effect on eating: more satiety and fullness, less hunger, and less intense food cravings.

All of these medicines slow the emptying of the stomach. That helps explain the stomach side effects, and it is why the SmPCs ask for care with some tablets taken at the same time, such as medicines with a narrow therapeutic index. For details on each substance, see our page on tirzepatide and our page on semaglutide.

Licensed use: the difference that decides the rest

A medicine is authorised for specific indications, and section 4.1 of its SmPC sets them out. Wegovy and Mounjaro are licensed for weight management, including weight loss and weight maintenance, in adults with obesity, or with overweight and at least one weight-related condition such as high blood pressure, abnormal blood fats, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. In each case the medicine is used together with a reduced-calorie diet and more physical activity.

Ozempic is licensed for adults with type 2 diabetes that is not controlled well enough, as an addition to diet and exercise, either on its own when metformin is not suitable or together with other diabetes medicines. Its SmPC lists no weight management indication. Ozempic and Wegovy contain the same substance, but the doses, the dose schedule and the licensed use are different, so one is not a stand-in for the other.

Mounjaro is the only one of the three licensed for both uses: weight management in adults, and type 2 diabetes in adults, adolescents and children aged 10 and over.

How the dose is built up

None of these medicines starts at its maintenance dose. Wegovy injections start at 0.25 mg once a week and rise every four weeks through 0.5 mg, 1 mg and 1.7 mg to 2.4 mg; the SmPC says this 16-week escalation is meant to reduce the likelihood of stomach symptoms. For some adults, under the conditions set out in section 4.2, the dose can be raised to 7.2 mg after at least four weeks on 2.4 mg, and it goes back to 2.4 mg if 7.2 mg brings no further improvement in weight.

Mounjaro starts at 2.5 mg once a week for four weeks, then 5 mg, with further 2.5 mg steps possible after at least four weeks on a dose; the maintenance doses are 5 mg, 10 mg and 15 mg. Ozempic, used for diabetes, starts at 0.25 mg and goes up to a maximum of 2 mg.

If stomach symptoms are significant, the Wegovy SmPC allows the next increase to be delayed or the previous dose to be used until they improve. Doses are specific to each product and are not interchangeable between them; a switch from one to another is a prescribing decision with its own starting point.

Wegovy as a tablet

Semaglutide for weight management is also licensed as a tablet taken once a day, for adults. The SmPC sets a starting dose of 1.5 mg, then 4 mg, 9 mg and 25 mg, with at least four weeks at each step. The tablet is taken on an empty stomach after at least 8 hours of fasting, swallowed whole with a sip of water, and you then wait at least 30 minutes before eating, drinking or taking other medicines. The SmPC also explains how to switch between the weekly 2.4 mg injection and the 25 mg tablet. Mounjaro and Ozempic have no tablet form in the product information.

What the trials showed, and what they cannot tell you

In the clinical trials described in section 5.1 of the Mounjaro SmPC, one trial compared the two weight management injections directly. In SURMOUNT-5, 751 adults with obesity, or overweight with a weight-related condition, received tirzepatide 15 mg or semaglutide 2.4 mg once a week for 72 weeks, with a lower dose allowed for people who did not tolerate it. Average body weight fell by 21.6% with tirzepatide and by 15.4% with semaglutide.

Those are averages from one trial, and they do not predict what happens to you. Some people do not tolerate a medicine at the dose that produced the average, and a medicine you cannot keep taking does not help you. Other conditions, other medicines, whether a weekly or daily schedule suits you and how you react to the first doses all count. Which medicine is suitable is a decision for a doctor who has your history, and the doctor may decide that none of them is.

Side effects most people notice

For the three weight management products the most frequently reported side effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation and abdominal pain. The SmPCs describe them as mostly mild or moderate and most common while the dose is being increased. Indigestion, reflux, burping, wind, bloating, tiredness and dizziness are also listed, and hair loss with Wegovy and Mounjaro. The frequencies in each SmPC come from that product's own trials, so they cannot be compared like for like between products.

Less common but more serious problems are named in the product information. Acute pancreatitis has been reported: severe stomach pain that does not go away, sometimes reaching the back, needs a doctor straight away. Gallstones and gallbladder inflammation are listed. Vomiting and diarrhoea can cause dehydration and, in rare cases, worse kidney function. In people with type 2 diabetes who also use insulin or a sulphonylurea, the risk of low blood sugar rises. The Wegovy SmPC also describes a very rare condition of the optic nerve (NAION) and says a sudden loss of vision needs an eye examination.

Who should not use them, and when to be careful

The only contraindication in section 4.3 of the Wegovy and Mounjaro SmPCs is hypersensitivity to the active substance or to an ingredient. Section 4.4 adds the situations that need caution. These include a history of pancreatitis, severe gastrointestinal disease or severe gastroparesis, diabetic eye disease in people with type 2 diabetes, and planned operations under general anaesthesia or deep sedation, because food can stay in the stomach for longer and cases of inhaling stomach contents have been reported. The Wegovy SmPC does not recommend it for people with type 1 diabetes, severe kidney impairment or severe heart failure, among others.

Pregnancy is a clear stop. Neither semaglutide nor tirzepatide is recommended during pregnancy, and both SmPCs recommend contraception for women who could become pregnant during treatment. Semaglutide should be stopped at least 2 months before a planned pregnancy and tirzepatide at least 1 month before. On breastfeeding they differ: Wegovy should not be used while breastfeeding, while the Mounjaro SmPC says tirzepatide could be considered.

On the contraceptive pill, the Mounjaro SmPC reports that a single dose lowered the peak levels of the pill hormones, a reduction it does not consider clinically relevant, with no dose adjustment of the pill required. The Wegovy SmPC says semaglutide is not expected to reduce the effect of oral contraceptives.

Products sold outside pharmacies

Semaglutide or tirzepatide offered for sale online without a prescription does not come through the regulated supply route described on this page. The HPRA states that it is illegal to sell prescription medicines online in Ireland and warns that buying them is dangerous. An authorised medicine is dispensed by a pharmacy, in the manufacturer's pen or pack, with the package leaflet inside.

What the medicines cost

We do not quote medicine prices. Our fee covers the doctor's assessment; you pay for the medicine at the pharmacy, at the pharmacy's price. What you pay for the medicine depends on the product, the strength and the pen, and it changes as the dose is increased. We make no claim about whether a medicine dispensed on this prescription counts towards a medical card or the Drugs Payment Scheme. How the costs are made up, and why the first month is not a guide to the rest, is explained in our article on what weight loss injections cost.

How a weight management request is assessed

Weight Loss Treatment is a written assessment by a doctor, both for starting a weight management medicine and for continuing one you already use. You fill in a medical questionnaire: you name the medicine or describe your situation and answer questions about your health, your other medicines and your conditions. There is no video call and no telephone consultation.

If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. The doctor may ask for records or test results, may advise you to be seen in person, and may decline. How Weight Loss Treatment works, and what the doctor checks, is described on our page on weight loss injections.

If the doctor issues a prescription, you receive it as a PDF by email. You print the PDF and take the printout to a pharmacy. A pharmacist in Ireland decides whether to dispense a prescription written by a doctor in another EEA country and may decline. This is not an Irish ePrescription and it is not sent through Healthmail.

Who reviewed this page

Medically reviewed by Damian Wojno, a doctor registered in Poland (licence no. 3211301, Regional Medical Chamber in Olsztyn). He is not on the register of the Irish Medical Council. The licensed uses, doses and warnings on this page come from the summaries of product characteristics published by the European Medicines Agency; the package leaflet in your pack is the reference for the product you use.

Is Ozempic the same as Wegovy?

They contain the same active substance, semaglutide, but they are different products. Wegovy is licensed for weight management and comes as weekly injections up to 2.4 mg, or 7.2 mg in some adults, and as a daily tablet. Ozempic is licensed only for adults with type 2 diabetes, with weekly doses up to 2 mg. The dose schedules are not interchangeable, and using Ozempic for weight loss alone falls outside its licence.

Mounjaro vs Wegovy: what is the difference?

Mounjaro contains tirzepatide, which acts on the GIP and GLP-1 receptors; Wegovy contains semaglutide, which acts on the GLP-1 receptor. Both are weekly injections licensed for weight management in adults, with different dose steps. Wegovy also exists as a daily tablet, and Mounjaro is also licensed for type 2 diabetes.

Which one should I choose?

That is a decision for a doctor who knows your history, not for a comparison page. The licensed use, your other conditions and medicines, how you tolerate the first doses and whether a weekly injection or a daily tablet suits you all matter. A doctor may also decide that none of these medicines is suitable for you.

Can I switch from Wegovy to Mounjaro?

A switch between products is a prescribing decision, not a swap you make at home. Each SmPC gives its own dose schedule, starting from a low dose, and the doses of semaglutide and tirzepatide are not interchangeable. The Wegovy SmPC describes switching only between its own weekly injection and its daily tablet. If you are considering a change, tell the doctor which product and dose you use now and how you have tolerated it.

Do these medicines affect the contraceptive pill?

According to the SmPCs, no dose adjustment of the pill is needed with tirzepatide, and semaglutide is not expected to reduce the effect of oral contraceptives. Both SmPCs recommend contraception for women who could become pregnant during treatment. If you vomit or have severe diarrhoea, check the leaflet of your contraceptive for what to do.

Do I need blood tests before starting?

It depends on your history. The doctor may ask for recent results, for example if you have diabetes, kidney or liver disease, or take a medicine that needs monitoring. You send them through the chat in your account. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder.